Diffusion Pharmaceuticals
Trans sodium crocetinate. | |
| Website | diffusionpharma.com |
|---|---|
Diffusion Pharmaceuticals Inc (
Research activities
Gainer invented the concept of oxygen diffusion-enhancing compounds and its specific embodiment, TSC, while a Professor of Chemical Engineering at the University of Virginia. He secured the first patent on the molecule and its uses in 2000. Before TSC's invention, he and colleagues conducted research on the effects of oxygen diffusion-enhancing compounds in various animal disease models, including
Clinical trials
In 2007, TSC was advanced into
Intellectual property
Between 2008 and 2017, Diffusion Pharmaceuticals expanded its intellectual property portfolio, having been awarded new patents (in the United States and internationally) that covered the synthesis and uses of bipolar trans carotenoid salts and related compounds in peripheral artery disease, cancer and other indications.[15] In 2011, TSC received an orphan drug designation from the United States Food and Drug Administration for the use of TSC as a radiosensitizer in the treatment of newly diagnosed GBM patients. In accordance with standard practice, the Orphan Drug designation for TSC confers benefits including enhanced patent protection and marketing rights, waiver of certain FDA filing fees and favorable tax treatment.[16] By mid-2017, the company had been issued 14 U.S. and 46 international patents.[15][6]
Awards
In 2012, Diffusion Pharmaceuticals won the Virginia Healthcare Innovators award in the “Medical Product or Device ” category for its development of TSC.[17]
References
- ^ "Diffusion Pharmaceuticals - Our Team / Board of Directors". Diffusion Pharmaceuticals. Retrieved September 10, 2021.
- ^ a b c "Company Overview of Diffusion Pharmaceuticals LLC". Bloomberg Businessweek. Archived from the original on January 10, 2013. Retrieved November 10, 2012.
- ^ a b US patent 6,060,511, Gainer J, "Trans-sodium crocetinate, methods of making and methods of use thereof", issued 2000-05-09
- ^ S2CID 71663644.
- ^ "Diffusion Pharmaceuticals Completes Merger with RestorGenex and Becomes Diffusion Pharmaceuticals Inc" (PDF). January 8, 2016. Retrieved May 25, 2020.
- ^ a b Chris Lange (May 26, 2019). "Diffusion Pharma's COVID-19 Treatment Takes a Big Step Forward With the FDA". Retrieved May 27, 2020.
- PMID 11706343.
- ^ "Navy adds to Diffusion Pharmaceuticals funding". TechJournal South. February 6, 2007. Archived from the original on February 14, 2015. Retrieved October 30, 2012.
- ^ "Diffusion Pharmaceuticals Raises $2.1 Million in Private Equity Round Human Testing of its Lead Compound TSC Planned for 2005". TechJournal South. Retrieved October 30, 2012.
- S2CID 25369069.
- PMID 19961314.
- PMID 18447715.
- ^ "Safety, Efficacy, and Pharmacokinetics (PK) Study of Trans Sodium Crocetinate (TSC) in Patients With Intermittent Claudication". ClinicalTrials.gov. 2008. Retrieved October 22, 2012.
- ^ "Diffusion Pharmaceuticals Announces FDA Accelerated Review of TSC Clinical Development Plan to Treat COVID-19 Patients with ARDS". Diffusion Pharmaceuticals. May 5, 2020. Retrieved May 25, 2020.
- ^ a b "Diffusion Pharmaceuticals: Intellectual Property". Diffusion Pharmaceuticals. Archived from the original on October 26, 2012. Retrieved October 30, 2012.
- ^ "USFDA Results of Orphan Drug Product Designations Search". Food and Drug Administration. Retrieved October 30, 2012.
- ^ "Diffusion Pharmaceuticals Wins 2012 VA Healthcare Innovators Award". Virginia Biotechnology Association. Archived from the original on January 13, 2013. Retrieved October 30, 2012.